The use of bispecific antibodies in tumor cell and tumor vasculature directed immunotherapy

Journal of Controlled Release

Volumn 64, Issue 1-3, 2000, Pages 229-239

  Molema, Grietje ^a   Kroesen, Bart Jan ^a   Helfrich, Wijnand ^a   Meijer, Dirk K F ^a   De Leij, Lou F M H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Angiogenesis; Bispecific antibody; Targeted therapy; Tumor cell; Tumor vasculature

Indexed keywords

BISPECIFIC ANTIBODY; DAUNORUBICIN; IMMUNOTOXIN; INTERLEUKIN 2; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANGIOGENESIS; CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DERIVATIZATION; DRUG TARGETING; EFFECTOR CELL; ENDOTHELIUM CELL; HUMAN; HYBRIDOMA; MACROPHAGE; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL; TUMOR VASCULARIZATION;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; EPITOPES; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0033982150     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00137-6     Document Type: Conference Paper

References (67)

1. Hellman S. Lancet (Foreword). 349:(suppl. II):1997.
2. Gore M., Riches P. The history of immunotherapy. Gore M., Riches P. Immunotherapy in Cancer. 1996;1-9 John Wiley and Sons, Chichester.
3. Fossa S.D. Interferons. Gore M., Riches P. Immunotherapy in Cancer. 1996;11-21 John Wiley and Sons, Chichester.
4. Atzpodien J., Schomburg A., Buer J. Interleukin-2. Gore M., Riches P. Immunotherapy in Cancer. 1996;43-75 John Wiley and Sons, Chichester.
5. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497.
6. Chen W., Peace D.J., Rovira D.K., You S.G., Cheever M.A. T-cell immunity to the joining region of p210BCR-ABL protein. Proc. Natl. Acad. Sci. USA. 89:1992;1468-1472.
7. Urban J.L., Schreiber H. Tumor antigens. Annu. Rev. Immunol. 10:1992;617-644.
8. Scott A.M., Cebon J. Clinical promise of tumour immunology. Lancet. 349:(Suppl 2):1997;SII19-SII22.
9. de Leij L., Helfrich W., Stein R., Mattes M.J. SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int. J. Cancer. 8:1994;60-63.
10. 111-DTPA-MOC31 in small cell lung carcinoma. J. Nucl. Med. 36:1995;2356-2362.
11. Pietersz G.A., McKenzie I.F.C. Antibody conjugates for the treatment of cancer. Immunol. Rev. 129:1992;57-80.
12. Wawrzynczak E.J. Antibody Therapy. 1995;Bios Scientific Publishers, Oxford.
13. Lane D.M., Eagle K.F., Begent R.H., Hope Stone L.D., Green A.J., Casey J.L., et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab′)2 antibodies. Br. J. Cancer. 70:1994;521-525.
14. Stone M.J., Sausville E.A., Fay J.W., Headlee D., Collins R.H., Figg W.D., et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood. 88:1996;1188-1197.
15. Wels W., Beerli R., Hellmann P., Schmidt M., Marte B.M., Kornilova E.S., et al. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int. J. Cancer. 60:1995;137-144.
16. Niculeescu-Duvaz I., Springer C.J. Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv. Drug Deliv. Rev. 26:1997;151-172.
17. Reilly R.M., Sandhu J., Alvarez Diez T.M., Gallinger S., Kirsh J., Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin. Pharmacokinet. 28:1995;126-142.
18. Thrush G.R., Lark L.R., Clinchy B.C., Vitetta E.S. Immunotoxins: an update. Annu. Rev. Immunol. 14:1996;49-71.
19. Begent R.H.J., Verhaar M.J., Chester K.A., Casey J.L., Green A.J., Napier M.P., et al. Clinical evidence of efficient tumor targeting based on a single-chain Fv antibody selected from a combinatorial library. Nature Med. 2:1996;979-984.
20. Molema G., de Leij L.F.M.H., Meijer D.K.F. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm. Res. 14:1997;2-10.
21. Molema G., Meijer D.K.F., de Leij L.F.M.H. Tumor vasculature targeted therapies: getting the players organized. Biochem. Pharmacol. 55:1998;1939-1945.
22. Dillman R.O. Antibodies as cytotoxic therapy. J. Clin. Oncol. 12:1994;1497-1515.
23. Wallace P.K., Howell A.L., Fanger M.W. Role of Fc gamma receptors in cancer and infectious disease. J. Leukoc. Biol. 55:1994;816-826.
24. Milstein C., Cuello A.C. Hybrid hybridomas and their use in immunohistochemistry. Nature. 305:1983;537-540.
25. Brennan M., Davison P.F., Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science. 229:1985;81-83.
26. Glennie M.J., McBride H.M., Worth A.T., Stevenson G.T. Preparation and performance of bispecific F(ab′gamma)2 antibody containing thioether-linked Fab′gamma fragments. J. Immunol. 139:1987;2367-2375.
27. Kostelny S.A., Cole M.S., Tso J.Y. Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 148:1992;1547-1553.
28. Holliger P., Prospero T., Winter G. 'Diabodies': small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA. 90:1993;6444-6448.
29. Helfrich W., Kroesen B.J., Roovers R.C., Westers L., Molema G., Hoogenboom H.R., et al. Construction and characterization of a bispecific diabody for retargeting T-cells to human carcinomas. Int. J. Cancer. 76:1998;232-239.
30. Morimoto K., Inouye K. A sensitive enzyme immunoassay of human thyroid-stimulating hormone (TSH) using bispecific F(ab′)2 fragments recognizing polymerized alkaline phosphatase and TSH. J. Immunol. Methods. 205:1997;81-90.
31. Peacock J.S., Colsky A.S., Pinto V.B. Lectins and antibodies as tools for studying cellular interactions. J. Immunol. Methods. 126:1990;147-157.
32. Bode C., Runge M.S., Branscomb E.E., Newell J.B., Matsueda G.R., Haber E. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator. J. Biol. Chem. 264:1989;944-948.
33. Taylor R.P., Martin E.N., Reinagel M.L., Nardin A., Craig M., Choice Q., et al. Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model. J. Immunol. 159:1997;4035-4044.
34. Renner C., Pfreundschuh M. Tumor therapy by immune recruitment with bispecific antibodies. Immunol. Rev. 145:1995;179-209.
35. Titus J.A., Garrido M.A., Hecht T.T., Winkler D.F., Wunderlich J.R., Segal D.M. Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice. J. Immunol. 138:1987;4018-4022.
36. Demanet C., Brissinck J., Van Mechelen M., Leo O., Thielemans K. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype×anti-CD3). J. Immunol. 147:1991;1091-1097.
37. Smans K.A., Hoylaerts M.F., Narisawa S., Millan J.L., de Broe M.E. Bispecific antibody-mediated lysis of placental and germ cell alkaline phosphatase targeted solid tumors in immunocompetent mice. Cancer Res. 55:1995;4383-4390.
38. Kroesen B.J., Helfrich W., Bakker A., Wubbena A.S., Bakker H., Kal H.B., et al. Reduction of EGP-2 positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat model. Int. J. Cancer. 61:1995;812-818.
39. Renner C., Jung W., Sahin U., Denfeld R., Pohl C., Trumper L., et al. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science. 264:1994;833-835.
40. Demanet C., Brissinck J., De Jonge J., Thielemans K. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood. 87:1996;4390-4398.
41. Garcia de Palazzo I., Holmes M., Gercel Taylor C., Weiner L.M. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16. Cancer Res. 52:1992;5713-5719.
42. Weiner L.M., Holmes M., Adams G.P., LaCreta F., Watts P., Garcia de Palazzo I. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res. 53:1993;94-100.
43. Stockmeyer B., Valerius T., Repp R., Heijnen I.A., Buhring H.J., Deo Y.M., et al. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res. 57:1997;696-701.
44. Heijnen I.A.F.M., Rijks L.J.M., Schiel A., Stockmeyer B., van Ojik H.H., Dechant M., et al. Generation of Her-2/neu-specific cytotoxic neutrophils (PMN) in vivo. Efficient arming of PMN by combines administration of granulocyte colony stimulating factor and FcgammaRI bispecific antibodies. J. Immunol. 159:1997;5629-5639.
45. Valerius T., Stockmeyer B., van Spriel A.B., Graziano R.F., van den Herik Oudijk I.E., Repp R., et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood. 90:1997;4485-4492.
46. Nitta T., Sato K., Yagita H., Okumura K., Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet. 335:1990;368-371.
47. Janssen R.A.J., Kroesen B.J., Buter J., Mesander G., Sleijfer D.T., The T.H., et al. Immunomodulatory effects of intravenous BIS-1 F(ab′)2 administration in renal cancer patients. Br. J. Cancer. 72:1995;795-799.
48. Kroesen B.J., Nieken J., Sleijfer D.T., Molema G., de Vries E.G.E., Groen H.J.M., et al. Approaches to lung cancer treatment using CD3×EGP-2 directed bispecific monoclonal antibody BIS-1. Cancer Immunol. Immunother. 45:1997;203-206.
49. Kroesen B.J., ter Haar A., Spakman H., Willemse P., Sleijfer D.T., de Vries E.G.E., et al. Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol. Immunother. 37:1993;400-407.
50. Kroesen B.J., Buter J., Sleijfer D.T., Janssen R.A.J., van der Graaf W.T.A., The T.H., et al. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br. J. Cancer. 70:1994;652-661.
51. Valone F.H., Kaufman P.A., Guyre P.M., Lewis L.D., Memoli V., Deo Y., et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol. 13:1995;2281-2292.
52. Weiner L.M., Clark J.I., Davey M., Li W.S., Garcia de Palazzo I., Ring D.B., et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 55:1995;4586-4593.
53. Kroesen B.J., Helfrich W., Molema G., de Leij L. Bispecific antibodies for the treatment of cancer in experimental animal models and man. Adv. Drug Deliv. Rev. 31:1998;105-129.
54. van de Winkel J.G.J., Bast B., de Gast G.C. Immunotherapeutic potential of bispecific antibodies. Immunol. Today. 18:1997;562-564.
55. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 26:1997;71-90.
56. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175:1972;409-416.
57. Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol. Oncol. 23:1984;217-225.
58. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
59. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
60. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
61. Burrows F.J., Watanabe Y., Thorpe P.E. A murine model for antibody-directed targeting to vascular endothelial cells in solid tumors. Cancer Res. 52:1992;5954-5962.
62. Huang X., Molema G., King S., Watkins L., Edgington T.S., Thorpe P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547-550.
63. Dvorak H.F., Sioussat T.M., Brown L.F., Berse B., Nagy J.A., Sotrel A., et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J. Exp. Med. 174:1991;1275-1278.
64. Sato T.N., Tozawa Y., Deutsch U., Wolburg Buchholz K., Fujiwara Y., Gendron Maguire M., et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 376:1995;70-74.
65. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 277:1997;55-60.
66. Pasqualini R., Koivunen E., Ruoslahti E. αv integrins as receptors for tumor targeting by circulating ligands. Nature Biotech. 15:1997;542-546.
67. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.